Physician profile
Mark A Oshaughnessy
NPI 1962494138
$790.79
in general payments reported to CMS, 2019-2025
15 companies · $45.20 in 2025
The $45.20 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $33.52 · 2021: $157 · 2022: $165 · 2023: $138 · 2024: $62.92 · 2025: $45.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $246.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $276.94 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $132.30 | 2023 | Opsumit, Uptravi |
| Heartflow, INC. | $86.24 | 2022 | |
| Janssen Pharmaceuticals, INC | $85.07 | 2019-2023 | Xarelto |
| Telix Pharmaceuticals | $48.46 | 2024 | Illuccix |
| Edwards Lifesciences Corporation | $43.83 | 2022 | |
| Kyowa Kirin, INC. | $24.35 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $20.85 | 2025 | Eliquis |
| Merck Sharp & Dohme LLC | $16.28 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.08 | 2019 | |
| Biotronik INC. | $14.64 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.46 | 2024 | |
| Glaxosmithkline, LLC. | $12.29 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Oshaughnessy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.